Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Brief Summary: This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort A will not have received any local brain therapy, and subjects in Cohort B will have received prior local therapy for brain metastases. Subjects will continue on treatment until disease progression, death, or unacceptable adverse event.


Options:
A: Arm Label: Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Investigator-Choice Chemotherapy (ICC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Dacarbazine, Drug: Temozolomide | Arm Label: ICC→Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Dacarbazine, Drug: Temozolomide | Arm Label: ICC→Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Dacarbazine, Drug: Temozolomide | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Pembrolizumab 10 mg/kg, Pembrolizumab 2 mg/kg | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC)
B: Arm Label: Arm I (adjuvant pembrolizumab); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Magnetic Resonance Imaging, Biological: Pembrolizumab, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (adjuvant and neoadjuvant pembrolizumab); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Magnetic Resonance Imaging, Biological: Pembrolizumab, Procedure: Therapeutic Conventional Surgery | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab) | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (adjuvant pembrolizumab), Arm II (adjuvant and neoadjuvant pembrolizumab)
C: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Single Arm
D: Arm Label: BMS-936558 3 mg/kg (IV); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 | Arm Label: Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: BMS-936558; Assigned to Arm(s): BMS-936558 3 mg/kg (IV) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)

Answer: C